Trenkwalder, Claudia

[["dc.bibliographiccitation.firstpage","87"],["dc.bibliographiccitation.journal","Sleep Medicine"],["dc.bibliographiccitation.lastpage","92"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Muntean, Maria-Lucia"],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Sixel-Doring, Friederike"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Suzuki, Keisuke"],["dc.contributor.author","Hirata, Koichi"],["dc.contributor.author","Zimmermann, Johannes"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T10:10:36Z"],["dc.date.available","2018-11-07T10:10:36Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Sleep disturbances are a major problem encountered by neurologists attending Parkinson's disease (PD) patients. The Parkinson's Disease Sleep Scale-2 (PDSS-2) assesses a wide spectrum of disease-specific sleep problems and is easy to administer as a patient self-rating scale. The validation study showed that the scale is reliable, valid, and precise. Until now, however, only one Japanese study has assessed cut-off scores to define poor sleepers. Objectives: In this context we aimed to determine the PDSS-2 cut-off values that define a sleep disturbance severe enough to require referral of the patient to a sleep center or the need for specific treatment. Methods: Inpatients with idiopathic PD consecutively admitted to our hospital were enrolled. Patients completed the PDSS-2. The attending physician, who was blinded to the PDSS-2 results, but familiar with the patients' history and current disease status, completed a questionnaire consisting of two general questions on the presence of PD-specific and non-PD related sleep problems. Statistical analysis was performed to determine cut-off values for the PDSS-2 and correlation with the physician's evaluation of sleep disturbance severity. A natural cohort of non-PD patients with sleep disorders represented the control group. Results: The sample consisted of 52 (56%) men and 41 (44%) women with an average age of 69.22 +/- 8.74 years. PDSS-2 showed a sensitivity of 77.6% and a specificity of 74.3% in relation to physician's evaluation of PD-specific sleep problems. According to the physician's evaluation, PD-specific sleep disturbances occurred in 62% of the patients. 83% of patients with PDSS-2 scores >= 18 had clinically relevant sleep disturbances compared to only 33% of PD patients with scores <18. The severity of PD-specific sleep problems was well correlated with the PDSS-2 total score (r = 0.49). Conclusions: To our knowledge, this is the first study to define PDSS-2 cut-off values for the severity of sleep disturbances in a European PD sample. Our study shows that scores >= 18 define clinically relevant PD-specific sleep disturbances. (C) 2016 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.sleep.2016.06.026"],["dc.identifier.isi","000388541900013"],["dc.identifier.pmid","27810191"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39888"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1878-5506"],["dc.relation.issn","1389-9457"],["dc.title","Clinically relevant cut-off values for the Parkinson's Disease Sleep Scale-2 (PDSS-2): a validation study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","143"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Neurology Neurosurgery & Psychiatry"],["dc.bibliographiccitation.lastpage","146"],["dc.bibliographiccitation.volume","71"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Appiah-Kubi, L. S."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T08:49:32Z"],["dc.date.available","2018-11-07T08:49:32Z"],["dc.date.issued","2001"],["dc.identifier.doi","10.1136/jnnp.71.2.143"],["dc.identifier.isi","000170105400001"],["dc.identifier.pmid","11459881"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21484"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","0022-3050"],["dc.title","Restless legs syndrome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","660"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Parkinsonism & Related Disorders"],["dc.bibliographiccitation.lastpage","665"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Martinez-Martin, Pablo"],["dc.contributor.author","Antonini, Angelo"],["dc.contributor.author","Brown, Richard G."],["dc.contributor.author","Friedman, Joseph H."],["dc.contributor.author","Onofrj, Marco"],["dc.contributor.author","Surmann, Erwin"],["dc.contributor.author","Ghys, Liesbet"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T09:23:14Z"],["dc.date.available","2018-11-07T09:23:14Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Non-motor symptoms of Parkinson's disease (PD) represent major causes of morbidity. RECOVER, a randomized controlled trial of rotigotine transdermal system, was the first prospective controlled trial to use the Non-Motor Symptoms Scale (NMSS) as an exploratory outcome for assessment of treatment effects on non-motor symptoms in PD. Rotigotine improved NMSS total score compared with placebo, and the \"Sleep/fatigue\" and \"Mood/apathy\" domains. This post hoc analysis further characterizes the effects of rotigotine on sleep/fatigue and mood/apathy. Methods: Patients with PD and unsatisfactory early-morning motor impairment were randomized to transdermal patches of rotigotine (2-16 mg/24 h) or placebo. Treatment was titrated to optimal dose over 1-8 weeks, maintained for 4 weeks. The NMSS was assessed at baseline and end of treatment. Post hoc analyses are presented for individual items of the \"Sleep/fatigue\" and \"Mood/apathy\" domains. The interpretation of p-values is considered exploratory in nature. Results: Of 287 patients randomized, NMSS data were available for 267 patients (178 rotigotine, 89 placebo). Within the \"Sleep/fatigue\" domain there was a significant difference, in favor of rotigotine, in change from baseline score in 1 of 5 items: \"fatigue (tiredness) or lack of energy\" (ANCOVA, p < 0.0001). Within the \"Mood/apathy\" domain, there were significant differences in favor of rotigotine in 4 of 7 items: \"lost interest in surroundings\" (p < 0.0001), \"lost interest in doing things\" (p < 0.0001), \"seems sad or depressed\" (p < 0.01), and \"difficulty experiencing pleasure\" (p < 0.05). Conclusions: Rotigotine transdermal system may improve non-motor symptoms such as fatigue, symptoms of depression, anhedonia, and apathy in patients with PD; further prospective controlled studies are required to confirm this post hoc analysis. (c) 2013 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.parkreldis.2013.02.018"],["dc.identifier.isi","000320750300003"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29532"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1873-5126"],["dc.relation.issn","1353-8020"],["dc.title","Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1351"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of Clinical Sleep Medicine"],["dc.bibliographiccitation.lastpage","1357"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Walters, Arthur S."],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Lee, Hochang B."],["dc.contributor.author","Picchietti, Daniel L."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Martinez-Martin, Pablo"],["dc.contributor.author","Stebbins, Glenn T."],["dc.contributor.author","Schrag, Anette"],["dc.date.accessioned","2018-11-07T09:45:33Z"],["dc.date.available","2018-11-07T09:45:33Z"],["dc.date.issued","2014"],["dc.description.abstract","Objectives: Over the last decade therapeutic, pathogenetic, epidemiological and genetic research in restless legs syndrome/Willis-Ekbom Disease (RLS/WED) has required the development of specific quality of life scales and sleep scales. A Movement Disorder Society Task Force formally evaluated the quality of these scales. Methods: A literature search retrieved 5 quality of life instruments specific to RLS. As per MDS protocol, each scale was evaluated by 3 criteria which included (a) use in RLS, (b) use by research or clinical groups other than the group that developed the scale, and (c) formal validation and adequate clinimetric properties. Scales were categorized as \"Recommended\" when all 3 criteria were met, \"Suggested\" when used for RLS but only one of the other criteria was met, and \"Listed\" when used in RLS but there was absence of the other two criteria. Details regarding the development, use and clinimetric properties of each instrument are summarized along with the recommendations of the Task Force. Results and Conclusion: The Restless Legs Syndrome Quality of Life Scale-Abetz (RLS-QOL-Abetz) is the only scale designated as Recommended for use in cross-sectional assessments and treatment-related changes in RLS quality of life. Daily diaries hold future promise for the evaluation of RLS symptoms without the need for retrospective recall. An important need is the development of pediatric RLS quality of life instruments."],["dc.identifier.doi","10.5664/jcsm.4300"],["dc.identifier.isi","000346354100017"],["dc.identifier.pmid","25348243"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34645"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.relation.issn","1550-9397"],["dc.relation.issn","1550-9389"],["dc.title","Review of Quality of Life Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","629"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Neurology Neurosurgery & Psychiatry"],["dc.bibliographiccitation.lastpage","635"],["dc.bibliographiccitation.volume","73"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Pal, S."],["dc.contributor.author","DiMarco, A."],["dc.contributor.author","Whately-Smith, C."],["dc.contributor.author","Bridgman, K."],["dc.contributor.author","Mathew, R."],["dc.contributor.author","Pezzela, F. R."],["dc.contributor.author","Forbes, A."],["dc.contributor.author","Hogl, Birgit"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T09:46:13Z"],["dc.date.available","2018-11-07T09:46:13Z"],["dc.date.issued","2002"],["dc.description.abstract","Background: No formal instruments are available for quantifying sleep problems in Parkinson's disease. Objective: To develop a new sleep scale to quantify the various aspects of nocturnal sleep problems in Parkinson's disease, which may occur in up to 96% of affected individuals. Methods: Employing a multidisciplinary team approach, a visual analogue scale was devised addressing 15 commonly reported symptoms associated with sleep disturbance in Parkinson's disease-the Parkinson's disease sleep scale (PDSS). In all, 143 patients with Parkinson's disease completed the PDSS, covering the entire spectrum of disease from newly diagnosed to advanced stage. As controls, 137 age healthy matched subjects also completed the scale. Test-retest reliability was assessed in a subgroup of subjects. The Epworth sleepiness scale was also satisfactorily completed by 103 of the patients with Parkinson's disease. Results: PDSS scores in the Parkinson group were significantly different from the healthy controls. Patients with advanced Parkinson's disease had impaired scores compared with early/moderate disease. Individual items of the scale showed good discriminatory power between Parkinson's disease and healthy controls. Relevant items of the PDSS correlated with excessive daytime sleepiness. The scale showed robust test-retest reliability. Conclusions: This appears to be the first description of a simple bedside screening instrument for evaluation of sleep disturbances in Parkinson's disease. A combination of subitems may help identify specific aspects of sleep disturbance, which in turn may help target treatment."],["dc.identifier.doi","10.1136/jnnp.73.6.629"],["dc.identifier.isi","000179631300008"],["dc.identifier.pmid","12438461"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34822"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","0022-3050"],["dc.title","The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.journal","European Neurology"],["dc.bibliographiccitation.lastpage","10"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Pal, S."],["dc.contributor.author","Bridgman, K."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.date.accessioned","2018-11-07T09:31:57Z"],["dc.date.available","2018-11-07T09:31:57Z"],["dc.date.issued","2001"],["dc.description.abstract","Sleep-related problems are common in Parkinson's disease (PD) and may occur due to the disease process, alteration in sleep architecture or nocturnal motor problems such as akinesia and dystonia. Neuropsychiatric problems and nocturia can also cause significant sleep disruption in PD. Poor sleep may lead to daytime consequences such as excessive daytime sleepiness or fatigue. As there are no PD-specific sleep scales, we have devised a simple visual analogue scale - the Parkinson's disease sleep scale (PDSS) which is aimed at formal quantification of various aspects of nocturnal sleep disturbance in PD. In this paper, we discuss the development of this scale, its clinical use and how the scale could be used to devise targeted treatment strategies for nocturnal problems in PD. Copyright (C) 2001 S. Karger AG, Basel."],["dc.identifier.doi","10.1159/000058047"],["dc.identifier.isi","000173176100002"],["dc.identifier.pmid","11741097"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31641"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.conference","Symposium on Management of Movement Disorders - The Challenge of 24-Hour Symptom Control"],["dc.relation.eventlocation","COPENHAGEN, DENMARK"],["dc.relation.issn","0014-3022"],["dc.title","Achieving 24-hour control of Parkinson's disease symptoms: Use of objective measures to improve nocturnal disability"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1343"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Journal of Clinical Sleep Medicine"],["dc.bibliographiccitation.lastpage","1349"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Walters, Arthur S."],["dc.contributor.author","Frauscher, Birgit"],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Benes, Heike"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Garcia-Borreguero, Diego"],["dc.contributor.author","Lee, Hochang B."],["dc.contributor.author","Picchietti, Daniel L."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Martinez-Martin, Pablo"],["dc.contributor.author","Stebbins, Glenn T."],["dc.contributor.author","Schrag, Anette"],["dc.date.accessioned","2018-11-07T09:45:32Z"],["dc.date.available","2018-11-07T09:45:32Z"],["dc.date.issued","2014"],["dc.description.abstract","Objectives: Over the last decade, increased research on therapy, pathogenesis, epidemiological and genetic aspects of restless legs syndrome/Willis-Ekbom Disease (RLS/WED) has necessitated development of diagnostic instruments specific to RLS. The Movement Disorder Society commissioned a task force to formally evaluate the available evidence on diagnostic instruments in RLS. Methods: A literature search identified 4 instruments specific to RLS. Each instrument was evaluated by 3 criteria, which included (a) use in RLS, (b) use by groups other than the group that developed the instrument, and (c) formal validation and adequate clinimetric properties. Instruments were then qualified as \"Recommended\" when all 3 criteria were met, \"Suggested\" when used for RLS but only one of the other criteria are met, and \"Listed\" when used in RLS but there is absence of the other 2 criteria. Details regarding the development, use, and clinimetric properties of each instrument are summarized, along with the recommendations of the committee. Results and Conclusion: The Recommended diagnostic instruments are the Hening Telephone Diagnostic Interview (HTDI), the Cambridge-Hopkins diagnostic questionnaire for RLS (CH-RLSq), and the RLS Diagnostic Index (RLS-DI). An unmet need is the development of a diagnostic instrument for pediatric RLS. Diagnostic instruments are particularly useful in studies where patients are not personally interviewed or examined in the office setting."],["dc.identifier.doi","10.5664/jcsm.4298"],["dc.identifier.isi","000346354100016"],["dc.identifier.pmid","25348242"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34643"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Acad Sleep Medicine"],["dc.relation.issn","1550-9397"],["dc.relation.issn","1550-9389"],["dc.title","Review of Diagnostic Instruments for the Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED): Critique and Recommendations"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1023"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Parkinsonism & Related Disorders"],["dc.bibliographiccitation.lastpage","1030"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Garcia-Ruiz, Pedro J."],["dc.contributor.author","LeWitt, Peter"],["dc.contributor.author","Katzenschlager, Regina"],["dc.contributor.author","Sixel-Doering, Friederike"],["dc.contributor.author","Henriksen, Tove"],["dc.contributor.author","Sesar, Angel"],["dc.contributor.author","Poewe, Werner"],["dc.contributor.author","Baker, Mary"],["dc.contributor.author","Ceballos-Baumann, Andres"],["dc.contributor.author","Deuschl, Guenther"],["dc.contributor.author","Drapier, Sophie"],["dc.contributor.author","Ebersbach, Georg"],["dc.contributor.author","Evans, Andrew"],["dc.contributor.author","Fernandez, Hubert"],["dc.contributor.author","Isaacson, Stuart"],["dc.contributor.author","van Laar, Teus"],["dc.contributor.author","Lees, Andrew J."],["dc.contributor.author","Lewis, Simon"],["dc.contributor.author","Martinez Castrillo, Juan Carlos"],["dc.contributor.author","Martinez-Martin, Pablo"],["dc.contributor.author","Odin, Per"],["dc.contributor.author","O'Sullivan, John"],["dc.contributor.author","Tagaris, Georgios"],["dc.contributor.author","Wenzel, Karoline"],["dc.date.accessioned","2018-11-07T09:52:20Z"],["dc.date.available","2018-11-07T09:52:20Z"],["dc.date.issued","2015"],["dc.description.abstract","Extensive published evidence supports the use of subcutaneously-administered apomorphine as an effective therapy for Parkinson's disease (PD) but to date no consensus recommendations have been available to guide healthcare professionals in the optimal application of apomorphine therapy in clinical practice. This document outlines best-practice recommendations for selecting appropriate candidates for apomorphine intermittent injection (the pen-injection formulation) or apomorphine continuousinfusion (the pump formulation), for initiating patients onto therapy and for managing their ongoing treatment. Apomorphine is a suitable therapeutic option for PD patients who experience troublesome 'off periods despite optimized treatment with oral PD medications. Due to its speed of onset, apomorphine injection is particularly suited to those patients requiring rapid, reliable relief of both unpredictable and predictable 'off' periods, those who require reliable and fast relief when anticipating an 'off', those with levodopa absorption or gastric emptying problems resulting in delayed or failed 'on', or for rapid relief of early morning dystonia or akinesia. Apomorphine infusionl is suited for patients whose 'off periods can no longer be adequately controlled by standard oral PD treatment or for those in whom rescue doses of apomorphine injection are effective but either needed too frequently (more than 4-6 times per day), or are associated with increasing dyskinesia. In addition to treating motor fluctuations, there is evidence that apomorphine infusion may be effective for the management of specific non-motor symptoms of PD associated with 'off' periods. Apomorphine infusion is less invasive than other non-oral treatment options for advancing disease, intrajejunal levodopa infusion and deep-brain stimulation. (C) 2015 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Britannia Pharmaceuticals Ltd."],["dc.identifier.doi","10.1016/j.parkreldis.2015.06.012"],["dc.identifier.isi","000361576600003"],["dc.identifier.pmid","26189414"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36106"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1873-5126"],["dc.relation.issn","1353-8020"],["dc.title","Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2585"],["dc.bibliographiccitation.issue","24"],["dc.bibliographiccitation.journal","Neurology"],["dc.bibliographiccitation.lastpage","2593"],["dc.bibliographiccitation.volume","87"],["dc.contributor.author","Winkelman, John W."],["dc.contributor.author","Armstrong, Melissa J."],["dc.contributor.author","Allen, Richard P."],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Ondo, William G."],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Zee, Phyllis C."],["dc.contributor.author","Gronseth, Gary S."],["dc.contributor.author","Gloss, David"],["dc.contributor.author","Zesiewicz, Theresa"],["dc.date.accessioned","2018-11-07T10:04:33Z"],["dc.date.available","2018-11-07T10:04:33Z"],["dc.date.issued","2016"],["dc.description.abstract","Objective: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. Methods: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. Results and recommendations: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B). Clinicians may consider prescribing levodopa (Level C). Few head-to-head comparisons exist to suggest agents preferentially. Cabergoline is rarely used (cardiac valvulopathy risks). Augmentation risks with dopaminergic agents should be considered. When treating periodic limb movements of sleep, clinicians should consider prescribing ropinirole (Level A) or pramipexole, rotigotine, cabergoline, or pregabalin (Level B). For subjective sleep measures, clinicians should consider prescribing cabergoline or gabapentin enacarbil (Level A), or ropinirole, pramipexole, rotigotine, or pregabalin (Level B). For patients failing other treatments for RLS symptoms, clinicians may consider prescribing prolonged-release oxycodone/naloxone where available (Level C). In patients with RLS with ferritin <= 75 mu g/L, clinicians should consider prescribing ferrous sulfate with vitamin C (Level B). When nonpharmacologic approaches are desired, clinicians should consider prescribing pneumatic compression (Level B) and may consider prescribing near-infrared spectroscopy or transcranial magnetic stimulation (Level C). Clinicians may consider prescribing vibrating pads to improve subjective sleep (Level C). In patients on hemodialysis with secondary RLS, clinicians should consider prescribing vitamin C and E supplementation (Level B) and may consider prescribing ropinirole, levodopa, or exercise (Level C)."],["dc.description.sponsorship","American Academy of Neurology"],["dc.identifier.doi","10.1212/WNL.0000000000003388"],["dc.identifier.isi","000392244200019"],["dc.identifier.pmid","27856776"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38716"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1526-632X"],["dc.relation.issn","0028-3878"],["dc.title","Practice guideline summary: Treatment of restless legs syndrome in adults Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1161"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","The Lancet Neurology"],["dc.bibliographiccitation.lastpage","1170"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Trenkwalder, Claudia"],["dc.contributor.author","Chaudhuri, Kallol Ray"],["dc.contributor.author","Martinez-Martin, Pablo"],["dc.contributor.author","Rascol, Olivier"],["dc.contributor.author","Ehret, Reinhard"],["dc.contributor.author","Valis, Martin"],["dc.contributor.author","Satori, Maria"],["dc.contributor.author","Krygowska-Wajs, Anna"],["dc.contributor.author","Marti, Maria J."],["dc.contributor.author","Reimer, Karen"],["dc.contributor.author","Oksche, Alexander"],["dc.contributor.author","Lomax, Mark"],["dc.contributor.author","DeCesare, Julia"],["dc.contributor.author","Hopp, Michael"],["dc.date.accessioned","2018-11-07T09:48:38Z"],["dc.date.available","2018-11-07T09:48:38Z"],["dc.date.issued","2015"],["dc.description.abstract","Background Pain is a common non-motor symptom of Parkinson's disease. We investigated the analgesic efficacy of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson's disease and chronic, severe pain. Methods We did this phase 2 study in 47 secondary care centres in the Czech Republic, Germany, Hungary, Poland, Romania, Spain, and the UK. We enrolled patients with Hoehn and Yahr Stage II-IV Parkinson's disease, at least one type of severe pain, and an average 24-h pain score of at least 6 (assessed on an 11-point rating scale from 0=no pain to 10=pain as bad as you can imagine). Participants were randomly assigned (1: 1) with a validated automated system (block size four) to either oral OXN PR or placebo for 16 weeks (starting dose oxycodone 5 mg, naloxone 2.5 mg, twice daily). Patients and investigators were masked to treatment assignment. The primary endpoint was average 24-h pain score at 16 weeks in the full analysis population. This study is registered with EudraCT (2011-002901-31) and ClinicalTrials.gov (NCT01439100). Findings We enrolled 202 patients; 93 were assigned to OXN PR and 109 to placebo; the full analysis population consisted of 88 patients versus 106 patients. Least squares mean average 24-h pain score at 16 weeks in the full analysis population was 5.0 (95% CI 4.5 to 5.5) in the OXN PR group versus 5.6 (5.1 to 6.0) in the placebo group (difference -0.6, 95% CI -1.3 to 0.0; p=0.058). Similar proportions of patients in each group had adverse events (60/92 [65%] vs 76/109 [70%]), treatment-related adverse events (52/92 [57%] vs 62/109 [57%]), and serious adverse events (5/92 [5%] vs 7/109 [6%]). Treatment-related nausea was more common in the OXN PR group than in the placebo group (16/92 [17%] vs 10/109 [9%]), as was treatment-related constipation (16/92 [17%] vs 6/109 [6%]). Interpretation The primary endpoint, based on the full analysis population at week 16, was not significant. Nonetheless, the results of this study highlight the potential efficacy of OXN PR for patients with Parkinson's disease-related pain and might warrant further research on OXN PR in this setting."],["dc.description.sponsorship","Sian Marshall of Siantifix (Cambridgeshire, UK) - Mundipharma Research"],["dc.identifier.doi","10.1016/S1474-4422(15)00243-4"],["dc.identifier.isi","000364855100011"],["dc.identifier.pmid","26494524"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35348"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1474-4465"],["dc.relation.issn","1474-4422"],["dc.title","Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]